Enviar artigo por via de e-mail Computer-aided prediction of biological activity spectra for organic compounds: the possibilities and limitations
- Autores: Poroikov V.V.1, Filimonov D.A.1, Gloriozova T.A.1, Lagunin A.A.1,2, Druzhilovskiy D.S.1, Rudik A.V.1, Stolbov L.A.1, Dmitriev A.V.1, Tarasova O.A.1, Ivanov S.M.1,2, Pogodin P.V.1
-
Afiliações:
- Institute of Biomedical Chemistry
- Pirogov Russian National Research Medical University
- Edição: Volume 68, Nº 12 (2019)
- Páginas: 2143-2154
- Seção: Reviews
- URL: https://journals.rcsi.science/1066-5285/article/view/243544
- DOI: https://doi.org/10.1007/s11172-019-2683-0
- ID: 243544
Citar
Acesso aberto
Acesso está concedido
Somente assinantes
Resumo
We describe the current version of the PASS program for prediction of biological activity spectra of organic compounds based on analysis of structure—activity relationships (SAR) for a training set containing information on more than 1000 000 biologically active organic compounds. The average accuracy of prediction for more than 5 000 types of biological activity exceeds a value of 0.96. To analyze quantitative SAR, the GUSAR program was developed. The advantages of GUSAR were demonstrated in a number of computational experiments. The local versions of the PASS and GUSAR programs, as well as 19 freely available web services were developed. The latter are freely accessible via the Internet at http://way2drug.com/dr. The web services at the Way2Drug portal are used by more than 24 000 researchers working in about 100 countries. Currently, more than 830 000 predictions were made, the most promising compounds were selected for chemical synthesis, and priorities for testing their biological activity were established. The PharmaExpert software was developed to analyze the results of the PASS- and GUSAR-based predictions and to search for chemical compounds with necessary biological activity spectra. Combined use of the PASS, GUSAR, and PharmaExpert programs enables an assessment of the pharmacotherapeutic, adverse, and toxic effects of new compounds based on the systems pharmacology.
Sobre autores
V. Poroikov
Institute of Biomedical Chemistry
Autor responsável pela correspondência
Email: vladimir.poroikov@ibmc.msk.ru
Rússia, 10/8 ul. Pogodinskaya, Moscow, 119121
D. Filimonov
Institute of Biomedical Chemistry
Email: vladimir.poroikov@ibmc.msk.ru
Rússia, 10/8 ul. Pogodinskaya, Moscow, 119121
T. Gloriozova
Institute of Biomedical Chemistry
Email: vladimir.poroikov@ibmc.msk.ru
Rússia, 10/8 ul. Pogodinskaya, Moscow, 119121
A. Lagunin
Institute of Biomedical Chemistry; Pirogov Russian National Research Medical University
Email: vladimir.poroikov@ibmc.msk.ru
Rússia, 10/8 ul. Pogodinskaya, Moscow, 119121; 1 ul. Ostrovityanova, Moscow, 117997
D. Druzhilovskiy
Institute of Biomedical Chemistry
Email: vladimir.poroikov@ibmc.msk.ru
Rússia, 10/8 ul. Pogodinskaya, Moscow, 119121
A. Rudik
Institute of Biomedical Chemistry
Email: vladimir.poroikov@ibmc.msk.ru
Rússia, 10/8 ul. Pogodinskaya, Moscow, 119121
L. Stolbov
Institute of Biomedical Chemistry
Email: vladimir.poroikov@ibmc.msk.ru
Rússia, 10/8 ul. Pogodinskaya, Moscow, 119121
A. Dmitriev
Institute of Biomedical Chemistry
Email: vladimir.poroikov@ibmc.msk.ru
Rússia, 10/8 ul. Pogodinskaya, Moscow, 119121
O. Tarasova
Institute of Biomedical Chemistry
Email: vladimir.poroikov@ibmc.msk.ru
Rússia, 10/8 ul. Pogodinskaya, Moscow, 119121
S. Ivanov
Institute of Biomedical Chemistry; Pirogov Russian National Research Medical University
Email: vladimir.poroikov@ibmc.msk.ru
Rússia, 10/8 ul. Pogodinskaya, Moscow, 119121; 1 ul. Ostrovityanova, Moscow, 117997
P. Pogodin
Institute of Biomedical Chemistry
Email: vladimir.poroikov@ibmc.msk.ru
Rússia, 10/8 ul. Pogodinskaya, Moscow, 119121
Arquivos suplementares
